Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (1): 145-150. doi: 10.19723/j.issn.1671-167X.2019.01.025

Previous Articles     Next Articles

Expression of hUTP14a in non-small cell lung cancer

Chun-feng ZHANG1,Yun LIU2,Min LU3,Xiao-juan DU4,△()   

  1. 1. Department of Medical Genetics, Peking University School of Basic Medical Sciences, Beijing 100191, China
    2. Peking University Centre of Medical and Health Analysis, Beijing 100191, China
    3. Department of Pathology, Peking University School of Basic Medical Sciences, Beijing 100191, China
    4. Department of Cell Biology, Peking University School of Basic Medical Sciences, Beijing 100191, China
  • Received:2018-09-27 Online:2019-02-18 Published:2019-02-26
  • Contact: Xiao-juan DU E-mail:duxiaojuan100@bjmu.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China(81874143)

RICH HTML

   

PDF (PC)

Abstract:

Objective: Human U three protein 14a (hUTP14a) facilitates tumorigenesis through promoting p53 and Rb degradation as well as enhancing c-Myc oncogenic activity. Moreover, hUTP14a expression is up-regulated in human hepatocellular cancer and colorectal cancer tissues. In this study, the expression of hUTP14a in non-small cell lung cancer (NSCLC) tissues was evaluated by immunohistochemistry staining (IHC). The relationship between hUTP14a expression levels and the clinical characteristics of the NSCLC patients were analyzed. Methods: Lung cancer tissues and the adjacent non-cancerous tissues were collected from 123 cases of NSCLC patients including 53 cases of squamous cell carcinoma (SCC) and 70 cases of adenocarcinoma (ADC), who had accepted surgical resection at Peking University Third Hospital from May 2003 to April 2006. The expression level of hUTP14a was determined by IHC in human NSCLC tissues and the adjacent non-cancerous tissues. The associations between hUTP14a expression and the clinical pathological variables including gender, age, tumor size, histological type, differentiation degree and clinical pathological stage were analyzed using the Pearson’s χ 2 test. Results: The expression rate of hUTP14a in NSCLC tissues was significantly higher than that in the non-cancerous tissues (37.4% vs. 0, P<0.001). The expressions of hUTP14a in lung ADC and SCC were 48.6% and 20.6%, respectively. The expression rate of hUTP14a in both lung ADC and SCC was significantly higher than that in the adjacent non-cancerous tissues (P<0.001). In addition, the expression rate of hUTP14a in lung ADC was significantly higher than that in SCC (χ 2=8.66, P=0.003). Furthermore, the expression rate of hUTP14a in the late pTNM stage of SCC was significantly higher than that in the early pTNM stage of SCC while hUTP14a expression level was not associated with pTNM stage of ADC. No correlation was found between hUTP14a expression and the other clinical pathologic features of the patients. Conclusion: Expression of hUTP14a was up-regulated in NSCLC tissues and was correlated with pTNM stage of SCC, suggesting that hUTP14a might possess a potential as a candidate marker for the early diagnosis screening of NSCLC.

Key words: hUTP14a, non-small-cell lung carcinoma, Immunohistochemistry, Squamous cell carcinoma, Adenocarcinoma

CLC Number: 

  • R734.2

Figure 1

Immunohistochemistry staining of hUTP14a in lung cancer tissues (×400) A, hUTP14a in adenocarcinoma tissue; B, hUTP14a in squamous carcinoma tissue."

Table 1

Clinical features and positive expression rate of hUTP14a in 123 patients with lung cancer*"

Clinicopathologic variables hUTP14a positive rate, n (%)
Total (n=123) SCC (n=53) Adenocarcinoma (n=70)
Gender (n=123)
Male (n=74) 25 (33.8) 10 (18.9) 15 (21.4)
Female (n=49) 21 (42.9) 2 (3.8) 19 (27.1)
Age/years (n=123)
≤60 (n=55) 20 (36.4) 8 (15.1) 12 (17.1)
>60 (n=68) 26 (38.2) 4 (7.5) 22 (31.4)
Tumor size/cm (n=123)
≤3 (n=81) 32 (39.5) 7 (13.2) 25 (35.7)
>3 (n=42) 14 (33.3) 5 (9.4) 9 (12.9)
Differentiationgrade (n=112)
Poorly differentiated (n=22) 8 (36.3) 2 (3.8) 6 (8.6)
Moderately differentiated (n=78) 30 (38.5) 6 (11.3) 24 (34.3)
Highly differentiated (n=12) 4 (33.3) 2 (3.8) 2 (2.9)
pTNM stage (n=101)
Ⅰ+Ⅱ (n=64) 16 (25.0) 3 (5.7) 13 (18.6)
Ⅲ+Ⅳ (n=37) 13 (35.1) 9 (16.9) 4 (5.7)

Table 2

The relationship between hUTP14a expression and clinicopathologic features in 123 patients with lung cancer*"

Clinicopathologic variables Total (n=123), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=123)
Male (n=74) 49 (66.2) 25 (33.8)
Female (n=49) 28 (57.1) 21 (42.9) 1.037 0.309
Age/years (n=123)
≤60 (n=55) 35 (63.6) 20 (36.4)
>60 (n=68) 42(61.8) 26 (38.2) 0.045 0.831
Histopathology (n=123)
SCC (n=53) 41 (77.4) 12 (22.6)
Adenocarcinoma (n=70) 36 (51.4) 34 (48.6) 8.662 0.003
Tumor size/cm (n=123)
≤3 (n=81) 49 (60.5) 32 (39.5)
>3 (n=42) 28 (66.7) 14 (33.3) 0.450 0.502
Differentiation grade (n=112)
Poorly differentiated (n=22) 14 (63.6) 8 (36.4)
Moderately differentiated (n=78) 48 (61.5) 30 (38.5)
Highly differentiated (n=12) 8 (66.7) 4 (33.3) 0.132 0.936
pTNM stage (n=101)
Ⅰ+Ⅱ (n=64) 48 (75.0) 16 (25.0)
Ⅲ+Ⅳ(n=37) 24 (64.9) 13 (35.1) 1.177 0.278

Table 3

The relationship between hUTP14a expression and clinicopathologic features in 53 lung SCC patients*"

Clinicopathologic variables SCC (n=53), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=53)
Male (n=44) 34 (77.3) 10 (22.7)
Female (n=9) 7 (77.8) 2 (22.2) 0.001 0.974
Age/years (n=53)
≤60 (n=24) 16 (66.7) 8 (33.3)
>60 (n=29) 25 (86.2) 4 (13.8) 2.863 0.091
Tumor size/cm (n=53)
≤3 (n=27) 20 (74.1) 7 (25.9)
>3 (n=26) 21 (80.8) 5 (19.2) 0.339 0.560
Differentiation grade (n=42)
Poorly differentiated (n=10) 8 (80.0) 2 (20.0)
Moderately differentiated (n=26) 20 (76.9) 6 (23.1)
Highly differentiated (n=6) 4 (66.7) 2 (33.3) 0.388 0.824
pTNM stage (n=54)
Ⅰ+Ⅱ (n=29) 26 (89.6) 3 (10.3)
Ⅲ+Ⅳ(n=25) 17 (68.0) 8 (32.0) 3.959 0.047

Table 4

The relationship between hUTP14a expression and clinicopathologic features in 70 lung adenocarcinoma patients*"

Clinicopathologic variables Adenocarcinoma (n=70), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=70)
Male (n=30) 15 (50.0) 15 (50.0)
Female (n=40) 21 (52.5) 19 (47.5) 0.043 0.836
Age/years (n=70)
≤60 (n=31) 19 (61.3) 12 (38.7)
>60 (n=39) 17 (43.6) 22 (56.4) 2.166 0.141
Tumor size/cm (n=70)
≤3 (n=54) 29 (53.7) 25 (46.3)
>3 (n=16) 7 (43.7) 9 (56.3) 0.490 0.484
Differentiation grade (n=70)
Poorly differentiated (n=12) 6 (50.0) 6 (50.0)
Moderately differentiated (n=52) 28(53.8) 24 (46.2)
Highly differentiated (n=6) 4 (66.7) 2 (33.3) 0.463 0.793
pTNM stage (n=47)
Ⅰ+Ⅱ (n=35) 22 (62.9) 13 (37.1)
Ⅲ+Ⅳ(n=12) 7 (58.3) 5 (12.9) 0.077 0.781
[1] Zhang L, Li M, Wu N , et al. Time trends in epidemiologic cha-racteristics and imaging features of lung adenocarcinoma: a population study of 21,113 cases in China[J]. PLoS One, 2015,10(8):e0136727.
doi: 10.1371/journal.pone.0136727 pmid: 4552856
[2] 王媛媛, 毕玉, 王在翔 , 等. 山东省肺癌患者生存分析[J]. 中国卫生统计, 2018,35(1):111-116.
[3] 黄文彦, 刘凯珊 . 以新视角观察p53家族在肺癌发生及治疗中的独特作用[J]. 中国肺癌杂志, 2013,16(8):422-425.
doi: 10.3779/j.issn.1009-3419.2013.08.06
[4] 李相国, 齐景宪, 易明福 . P16、Rb和PCNA在非小细胞肺癌的表达及临床意义[J]. 临床肺科杂志, 2008,13(8):1002-1004.
doi: 10.3969/j.issn.1009-6663.2008.08.023
[5] Scheffner M, Huibregtse JM, Vierstra RD , et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53[J]. Cell, 1993,75(3):495-505.
doi: 10.1016/0092-8674(93)90384-3 pmid: 8221889
[6] Uchida C, Miwa S, Kitagawa K , et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation[J]. EMBO J, 2005,24(1):160-169.
doi: 10.1038/sj.emboj.7600486 pmid: 15577944
[7] Sdek P, Ying H, Chang DL , et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein[J]. Mol Cell, 2005,20(5):699-708.
doi: 10.1016/j.molcel.2005.10.017 pmid: 16337594
[8] Hu LL, Wang JN, Liu Y , et al. A small ribosomal subunit (SSU) processome component, the human U3 protein 14A (hUTP14A) binds p53 and promotes p53 degradation[J]. J Biol Chem, 2011,286(4):3119-3128.
doi: 10.1074/jbc.M110.157842 pmid: 21078665
[9] Liu HJ, Wang JN, Liu Y , et al. Human U3 protein14a is a novel type ubiquitin ligase that binds RB and promotes RB degradation depending on a leucine-rich region[J]. Biochim Biophys Acta Mol Cell Res, 2018,1865(11 Pt A):1611-1620.
doi: 10.1016/j.bbamcr.2018.08.016
[10] Zhang JY, Ren PW, Xu D , et al. Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc [J]. Cancer Letters, 2018, 440- 441:106-115.
doi: 10.1016/j.canlet.2018.10.010
[11] Zhang JY, Xu D, Liu ZZ , et al. Human U three protein 14a expression is increased in hepatocellular carcinoma and associated with poor prognosis[J]. Chin Med J (Engl), 2017,130(4):470-476.
doi: 10.4103/0366-6999.199839 pmid: 5324385
[12] Ma T, Lu CX, Guo YF , et al. Human U3 protein 14a plays an anti-apoptotic role in cancer cells[J]. Bio Chem, 2017,398(11):1247-1257.
[13] Groome PA, Bolejack V, Crowley JJ , et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J]. J Thorac Oncol, 2007,2(8):694-705.
doi: 10.1097/JTO.0b013e31812d05d5 pmid: 17762335
[14] Zhang Y, Xiong Y, Yarbrough WG . ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways[J]. Cell, 1998,92(6):725-734.
doi: 10.1016/S0092-8674(00)81401-4
[15] Leduc C, Claverie P, Eymin B , et al. p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation[J]. Oncogene, 2006,25(30):4147-4154.
doi: 10.1038/sj.onc.1209446 pmid: 16501607
[16] Bozcuk H, Gumus A, Ozbilim G , et al. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer[J]. Med Sci Monit, 2005,11(6):11-20.
doi: 10.1051/medsci/2005216-7669 pmid: 15917726
[17] 张丽华, 侯振江 . p53在肺癌研究中的进展[J]. 临床肺科杂志, 2006,11(1):59-60.
doi: 10.3969/j.issn.1009-6663.2006.01.030
[1] Hao FU, Luyan SHEN, Bingyang HUANG, Shaohua MA. Clinical strategies for perioperative management of esophageal squamous cell carcinoma in the immunotherapy era [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 266-271.
[2] Jialin LI, Liqiao CHEN, Jiatian TANG, Yan WU, Anqiang WANG. Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 399-404.
[3] Ye ZHAO, Xiaoli DIAO, Yan XIONG. Application of cell transfer technology in pathological diagnosis of micro-volume cell fluid [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 208-213.
[4] Xiaolin WANG, Luyao LI, Wen ZHANG, Hongyan WANG. Clinicopathological analysis of mesonephric-like adenocarcinoma in the corpusuteri: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1208-1212.
[5] Weihua HOU, Shujie SONG, Zhongyue SHI, Lu LIU, Mulan JIN. Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 1005-1009.
[6] Shang XIE, Luming WANG, Xinyuan ZHANG, Qiushi FENG, Yangyang XIA, Ziwei DAI, Xiaofeng SHAN, Zhigang CAI. Construction and application of oral squamous cell carcinoma organoid bank [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 847-851.
[7] Xiaoyong YANG, Fan ZHANG, Lulin MA, Cheng LIU. Clinical characteristics and influencing factors of extraglandular invasion of prostatic ductal adenocarcinoma [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 956-960.
[8] Li XU, Wen SHI, Yuehua LI, Yajun SHEN, Shang XIE, Xiaofeng SHAN, Zhigang CAI. LIM and calponin homology domains 1 may function as promising biological markers to aid in the prognostic prediction of oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 19-25.
[9] Minying MA, Xiaoqin CHAO, Yang ZHAO, Guoting ZHAO. Effects of LncRNA SNHG20 on epithelial mesenchymal transition and microtubule formation in human oral squamous cell carcinoma cells through targeted regulation of the miR-520c-3p/RAB22A pathway [J]. Journal of Peking University (Health Sciences), 2025, 57(1): 26-32.
[10] Yaqing MAO, Zhen CHEN, Yao YU, Wenbo ZHANG, Yang LIU, Xin PENG. Impact of type 2 diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1089-1096.
[11] Dan LUO, Haijian HUANG, Xin CHEN, Xiaoyan CHEN. Primary uterine hepatoid adenocarcinoma: Clinicopathological analysis of 2 cases and literature review [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1126-1131.
[12] Junqi SU,Xiaoying WANG,Zhiqiang SUN. Establishment and verification of a prognostic nomogram for survival of tongue squamous cell carcinoma patients who underwent cervical dissection [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 120-130.
[13] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[14] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[15] Bo-han NING,Qing-xia ZHANG,Hui YANG,Ying DONG. Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 366-369.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd